SB Investment Advisers (UK)’s Ginkgo Bioworks DNA Stock Holding History

SB Investment Advisers (UK)’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.05M	Hold	610,729	–	–	0.08%	9
2026 Q1	$3.74M	Hold	610,729	–	–	0.05%	10
2025 Q4	$5.08M	Hold	610,729	–	–	0.05%	10
2025 Q3	$8.9M	Hold	610,729	–	–	0.07%	10
2025 Q2	$6.87M	Hold	610,729	–	–	0.05%	10
2025 Q1	$3.48M	Hold	610,729	–	–	0.03%	10
2024 Q4	$6M	Hold	610,729	–	–	0.05%	10
2024 Q3	$4.98M	Sell	610,729 -1	-0%	-$10	0.04%	11
2024 Q2	$8.17M	Hold	610,730	–	–	0.08%	11
2024 Q1	$28.3M	Hold	610,730	–	–	0.28%	11
2023 Q4	$41.3M	Hold	610,730	–	–	0.37%	11
2023 Q3	$44.2M	Hold	610,730	–	–	0.36%	11
2023 Q2	$45.4M	Hold	610,730	–	–	0.35%	11
2023 Q1	$32.5M	Hold	610,730	–	–	0.27%	13
2022 Q4	$41.3M	Buy	+610,730	New	+$56.2M	0.34%	13

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

SB Investment Advisers (UK)'s DNA Position: Q2 2026 in Review

SB Investment Advisers (UK) held its Ginkgo Bioworks (DNA) position steady in Q2 2026 at 610,729 shares worth $6.05M. The position accounts for 0.08% of the portfolio, ranked #9.

SB Investment Advisers (UK) first reported a position in DNA in Q4 2022 and has held it in 15 quarters since. The position peaked at $45.4M in Q2 2023. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

SB Investment Advisers (UK) held 610,729 shares of Ginkgo Bioworks worth $6.05M as of Q2 2026.
SB Investment Advisers (UK) left its Ginkgo Bioworks share count unchanged in Q2 2026.
Ginkgo Bioworks made up 0.08% of SB Investment Advisers (UK)'s portfolio in Q2 2026, its #9 holding.
SB Investment Advisers (UK) first reported a position in Ginkgo Bioworks in Q4 2022 and has held it in 15 quarters since.
SB Investment Advisers (UK)'s Ginkgo Bioworks position peaked at $45.4M in Q2 2023.
184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on SB Investment Advisers (UK)'s 13F filing for Q2 2026, filed 14 Aug 2026.